Population-Based Health Screening

Population-based health screening systematically offers tests to an eligible population, including people without symptoms, to identify possible disease or risk factors early. Positive results require diagnostic confirmation; screening is worthwhile only when early detection produces a favourable balance of benefits, harms and costs. Screening can cause overdiagnosis by detecting genuine abnormalities that would never have caused symptoms or death.

When population screening is justified

A high disease burden alone does not justify screening. The programme must satisfy linked epidemiological, clinical and health-system criteria.

• The disease should be an important public-health problem with a sufficiently understood natural history.
• A detectable preclinical or early stage should exist, and treating it early should improve outcomes compared with waiting for symptoms.
• The screening test should be safe, accurate, simple and acceptable, with suitable sensitivity and specificity for the population.
• Facilities for diagnostic confirmation and effective treatment must be available to those who screen positive.
• Expected benefits should outweigh false positives, false negatives, overdiagnosis, anxiety and treatment-related harms.
• Screening should be cost-effective relative to other health priorities and organised as a continuing programme with agreed intervals.

India's screening pathway

India targets adults aged 30 years and above for screening of common NCDs through community outreach and primary-care facilities.

• Frontline workers enumerate eligible people, assess risks, mobilise them and support follow-up.
• Standard tests cover hypertension, diabetes, oral cancer, breast cancer and cervical cancer, with sex-specific cancer screening.
• An abnormal screen requires diagnostic confirmation because a screening test is not a diagnosis.
• Confirmed cases are linked to treatment, counselling, referral and continuing follow-up.

How screening produces overdiagnosis

Screening examines apparently healthy people and therefore searches a large reservoir of silent abnormalities. Some are slow-growing, non-progressive or spontaneously regressing conditions that would never become clinically important during the person's lifetime, especially where competing causes of death intervene.

• Unlike a false positive, overdiagnosis identifies a real abnormality but misclassifies its future clinical significance.
• More sensitive tests, lower diagnostic thresholds and repeated screening increase the chance of detecting such abnormalities.
• Once labelled as disease, an overdiagnosed condition may trigger biopsies, surgery, medicines or radiation, producing overtreatment without corresponding health benefit.
• Overdiagnosis can inflate incidence and survival measured from diagnosis without reducing disease-specific mortality, partly through lead-time bias.
• Whether an individual case was overdiagnosed is usually unknowable; its extent is assessed at the population level.

Benefits and programme safeguards

Screening moves detection beyond symptom-driven attendance because many NCDs remain asymptomatic initially, but safeguards must connect early detection with better outcomes.

• Broad coverage and standard protocols can enable earlier treatment while reducing dependence on awareness and care-seeking behaviour.
• Reliable tests, trained personnel, quality assurance, referral transport, treatment capacity and patient tracking sustain the continuum of care.
• Evidence-based eligibility, test thresholds and screening intervals should limit unnecessary testing and detection.
• Diagnostic confirmation, clear risk communication and shared decision-making can reduce anxiety and premature treatment.
• Equitable outreach should prevent exclusion by gender, income, geography or health literacy; evaluation should track coverage, confirmation, treatment initiation, outcomes and harms.